Kuks P, Kole T, Kraft M, Siddiqui S, Fabbri L, Rabe K
ERJ Open Res. 2025; 11(1).
PMID: 39963164
PMC: 11831683.
DOI: 10.1183/23120541.00616-2024.
Lommatzsch M, Blumchen K, Beck L, Bousquet J, Brusselle G, Fokkens W
EClinicalMedicine. 2025; 80:103050.
PMID: 39867971
PMC: 11764424.
DOI: 10.1016/j.eclinm.2024.103050.
Wongsa C, Wongyikul P, Chokevittaya P, Nititammaluk A, Soe K, Phinyo P
J Allergy Clin Immunol Glob. 2024; 4(1):100366.
PMID: 39649686
PMC: 11625304.
DOI: 10.1016/j.jacig.2024.100366.
Varricchi G, Poto R, Lommatzsch M, Brusselle G, Braido F, Virchow J
Allergy. 2024; 80(2):408-422.
PMID: 39520155
PMC: 11804314.
DOI: 10.1111/all.16382.
Kermani N, Li C, Versi A, Badi Y, Sun K, I Abdel-Aziz M
Clin Transl Med. 2024; 14(7):e1771.
PMID: 39073027
PMC: 11283589.
DOI: 10.1002/ctm2.1771.
Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.
Liu T, Woodruff P, Zhou X
Eur Respir J. 2024; 64(2).
PMID: 38697650
PMC: 11325267.
DOI: 10.1183/13993003.00826-2023.
Airway remodelling in asthma and the epithelium: on the edge of a new era.
Varricchi G, Brightling C, Grainge C, Lambrecht B, Chanez P
Eur Respir J. 2024; 63(4).
PMID: 38609094
PMC: 11024394.
DOI: 10.1183/13993003.01619-2023.
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Russell R, Boulet L, Brightling C, Pavord I, Porsbjerg C, Dorscheid D
Eur Respir J. 2024; 63(4).
PMID: 38453256
PMC: 10991852.
DOI: 10.1183/13993003.01397-2023.
Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis.
Hoshino M, Akitsu K, Ohtawa J, Kubota K
J Allergy Clin Immunol Glob. 2024; 3(2):100206.
PMID: 38328802
PMC: 10847160.
DOI: 10.1016/j.jacig.2024.100206.
Regulatory ILC2-Role of IL-10 Producing ILC2 in Asthma.
Fard N, Xiao M, Sehmi R
Cells. 2023; 12(21).
PMID: 37947634
PMC: 10650705.
DOI: 10.3390/cells12212556.
Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.
Baker J, Shaw D
Handb Exp Pharmacol. 2023; 285:369-451.
PMID: 37709918
DOI: 10.1007/164_2023_679.
2022 Year in Review: Pediatric Asthma.
Baker J
Respir Care. 2023; 68(10):1430-1437.
PMID: 37160339
PMC: 10506641.
DOI: 10.4187/respcare.10913.
Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma.
Cao T, Luu Quoc Q, Yang E, Moon J, Shin Y, Ryu M
Allergy Asthma Immunol Res. 2023; 15(4):451-472.
PMID: 37075799
PMC: 10359643.
DOI: 10.4168/aair.2023.15.4.451.
Tiotropium Bromide Improves Neutrophilic Asthma by Recovering Histone Deacetylase 2 Activity.
An T, Kim J, Hur J, Park C, Lim J, Kim S
J Korean Med Sci. 2023; 38(12):e91.
PMID: 36974400
PMC: 10042725.
DOI: 10.3346/jkms.2023.38.e91.
Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy.
Gao N, Rezaee F
Pharmaceutics. 2022; 14(12).
PMID: 36559113
PMC: 9786141.
DOI: 10.3390/pharmaceutics14122619.
Dose-Response Effect of Saccharomyces cerevisiae UFMG A-905 on the Prevention of Asthma in an Animal Model.
Milani T, Sandy C, Calazans A, Silva R, Fonseca V, Martins F
Probiotics Antimicrob Proteins. 2022; 16(1):53-61.
PMID: 36445686
DOI: 10.1007/s12602-022-10014-w.
Neutrophil Extracellular Traps in Asthma: Friends or Foes?.
Poto R, Shamji M, Marone G, Durham S, Scadding G, Varricchi G
Cells. 2022; 11(21).
PMID: 36359917
PMC: 9654069.
DOI: 10.3390/cells11213521.
Challenges in severe asthma: Do we need new drugs or new biomarkers?.
Adatia A, Vliagoftis H
Front Med (Lausanne). 2022; 9:921967.
PMID: 36237537
PMC: 9550875.
DOI: 10.3389/fmed.2022.921967.
IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma.
Badi Y, Salcman B, Taylor A, Rana B, Kermani N, Riley J
Allergy. 2022; 78(1):156-167.
PMID: 35986608
PMC: 10086999.
DOI: 10.1111/all.15487.
Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells.
Helou D, Quach C, Fung M, Painter J, Hurrell B, Loh Y
J Allergy Clin Immunol. 2022; 151(2):526-538.e8.
PMID: 35963455
PMC: 9905221.
DOI: 10.1016/j.jaci.2022.07.022.
